References
- Baldini S, Rigacci L, Carrai V, Fjerza R, Alterini R, Bosi A. Longterm follow-up of concomitant treatment with romiplostim and warfarin in a patient with immune thrombocytopenia and severe cardiac comorbidities. Platelets 2012, [Epub ahead of print]
- Cantoni N, Heizmann M, Bargetzi M. Immune thrombocytopenia and anticoagulation: The role of romiplostim in the early treatment. Br J Haematol 2012; 157: 639–641
- Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. The Lancet 2008; 371: 395–403
- Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebo controlled trial. The Lancet 2009; 373: 641–648
- Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A, EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia (ITP): Results of the longterm, open-label EXTEND study. Blood 2013; 121: 537–545
- Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009; 113: 2386–2393
- Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168–186
- Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS; 2006.